Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
Holding VALN?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.51Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: 3.40%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Neutral
Valneva's earnings call reflects a balanced view with strong product sales growth, a positive financial turnaround, and strategic advancements in R&D. However, challenges persist with the slow uptake of IXCHIQ in the US and increased costs impacting margins. The company is optimistic about future growth prospects and sustained profitability from 2027 onwards.Company Guidance
In the recent earnings call, Valneva provided updated guidance and performance metrics for the first nine months of 2024. Product sales reached €112.5 million, showing a 12% growth over the previous year, with IXIARO sales leading at €66 million, marking a 31% increase. The company narrowed its full-year product sales guidance to €160-€170 million, with total revenues expected between €170-€180 million. Valneva's R&D expenses rose to €48.6 million, reflecting ongoing tech transfers to its new manufacturing site in Scotland. Despite a slow uptake of IXCHIQ in the U.S., the company remains optimistic about its long-term prospects and expects its commercial business to be cash-generative by 2025. Furthermore, Valneva anticipates sustained profitability by 2027, driven by the Lyme disease vaccine program, pending successful Phase III results and regulatory filings anticipated in 2026. The firm maintains a robust cash position of over €150 million, supporting its strategic initiatives and R&D pipeline advancements.Product Sales Growth
Product sales for the first nine months of 2024 reached €112.5 million, growing 12% over the prior year on a comparable basis. IXIARO sales increased 31% year-over-year, driven by strong growth in both the travel segment and US military.
Strong Cash Position
Valneva reported a cash position of €156.3 million as of September 30, 2024, with a significant reduction in cash use from €136 million in the first nine months of 2023 to €76.3 million in the current year.
Advancements in R&D Pipeline
Valneva's R&D execution is on track, with significant progress in Lyme disease vaccine development and chikungunya vaccine IXCHIQ, which has shown strong safety and immunogenicity.
Positive Financial Performance
The company reported an operating profit of €34.2 million compared to an operating loss of €57.2 million the previous year. Adjusted EBITDA improved from minus €46 million to positive €48.6 million.
Strategic Partnerships
Valneva has established important partnerships, including with CEPI for chikungunya development and LimmaTech for Shigella, supporting its strategic positioning and development efforts.
---
VALN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VALN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $5.59 | $5.48 | -1.97% |
| Aug 13, 2024 | $6.94 | $7.45 | +7.35% |
| May 07, 2024 | $7.50 | $7.50 | 0.00% |
| Mar 20, 2024 | $7.92 | $7.10 | -10.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Valneva (VALN) report earnings?
Valneva (VALN) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Valneva (VALN) earnings time?
Valneva (VALN) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VALN EPS forecast?
VALN EPS forecast for the fiscal quarter 2024 (Q4) is -0.18.
---